Published in Transl Androl Urol on September 01, 2014
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74
Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA (2012) 33.54
The metabolic syndrome. Lancet (2005) 19.47
Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med (1999) 16.30
Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord (1998) 11.96
Prevalence of kidney stones in the United States. Eur Urol (2012) 9.42
Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int (2003) 9.11
Obesity, weight gain, and the risk of kidney stones. JAMA (2005) 5.34
Role of oxidative stress in atherosclerosis. Am J Cardiol (2003) 3.66
Diabetes mellitus and the risk of nephrolithiasis. Kidney Int (2005) 3.17
The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int (2004) 2.89
Body size and 24-hour urine composition. Am J Kidney Dis (2006) 2.27
The role of overweight and obesity in calcium oxalate stone formation. Obes Res (2004) 2.26
Impact of insulin resistance, insulin and adiponectin on kidney stones in the Japanese population. Int J Urol (2010) 2.20
A population study of 50-year-old men. An analysis of the non-participation group. Acta Med Scand (1965) 2.16
Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J (2004) 2.09
Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care (2002) 2.07
Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol (2007) 2.02
Impact of body weight on urinary electrolytes in urinary stone formers. Urology (2000) 1.94
Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988-1994. Am J Kidney Dis (2008) 1.91
Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol (2006) 1.90
Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int (2002) 1.78
Body size and risk of kidney stones. J Am Soc Nephrol (1998) 1.78
Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients. J Urol (2004) 1.70
Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int (2000) 1.62
Increased risk of diabetes in patients with urinary calculi: a 5-year followup study. J Urol (2011) 1.60
Epidemiologic aspects of overweight and obesity in the United States. Physiol Behav (2005) 1.59
Nephrolithiasis and risk of hypertension. Am J Hypertens (1998) 1.56
Renal handling of citrate. Kidney Int (1990) 1.51
Essential arterial hypertension and stone disease. Kidney Int (1999) 1.49
Kidney stones associate with increased risk for myocardial infarction. J Am Soc Nephrol (2010) 1.44
The primary stone event: a new hypothesis involving a vascular etiology. J Urol (2004) 1.38
Nephrolithiasis and risk of hypertension in women. Am J Kidney Dis (1998) 1.38
Apatite plaque particles in inner medulla of kidneys of calcium oxalate stone formers: osteopontin localization. Kidney Int (2005) 1.37
Metabolic syndrome and uric acid nephrolithiasis. Semin Nephrol (2008) 1.36
Influence of body size on urinary stone composition in men and women. Urol Res (2006) 1.36
The vicious circle between oxidative stress and inflammation in atherosclerosis. J Cell Mol Med (2009) 1.35
Possible role of carbohydrate-induced calciuria in calcium oxalate kidney-stone formation. N Engl J Med (1969) 1.32
Kidney stones and subclinical atherosclerosis in young adults: the CARDIA study. J Urol (2011) 1.31
Kidney stone disease and risk factors for coronary heart disease. Int J Urol (2005) 1.27
Renal tubular cell damage and oxidative stress in renal stone patients and the effect of potassium citrate treatment. Urol Res (2004) 1.27
Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost (2002) 1.27
Kidney stones and hypertension: population based study of an independent clinical association. BMJ (1990) 1.26
Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers. J Urol (2010) 1.24
Association of metabolic syndrome traits and severity of kidney stones: results from a nationwide survey on urolithiasis in Japan. Am J Kidney Dis (2013) 1.23
A prospective study of hypertension and the incidence of kidney stones in men. J Hypertens (1999) 1.17
Lipid peroxidation and its correlations with urinary levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones. Urology (2003) 1.15
A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J (2007) 1.15
Nephrolithiasis and increased blood pressure among females with high body mass index. Am J Kidney Dis (2005) 1.12
NADPH oxidase-derived reactive oxygen species: involvement in vascular physiology and pathology. Cell Tissue Res (2010) 1.11
Association between metabolic syndrome and the presence of kidney stones in a screened population. Am J Kidney Dis (2011) 1.10
Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality--results of prospective analysis for the Atherosclerosis Risk in Communities study. J Intern Med (2007) 1.09
Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis (2000) 1.05
Nephrolithiasis is associated with an increased prevalence of cardiovascular disease. Nephrol Dial Transplant (2010) 1.04
Salt sensitivity in humans is associated with abnormal acid-base regulation. Hypertension (1990) 1.01
Urinary 8-hydroxydeoxyguanosine is elevated in patients with nephrolithiasis. Urol Res (2007) 1.00
Renal inter-alpha-trypsin inhibitor heavy chain 3 increases in calcium oxalate stone-forming patients. Kidney Int (2007) 0.99
Elevated blood pressure and positive history of kidney stones: results from a population-based study. J Hypertens Suppl (1988) 0.98
Histochemical detection of esterified cholesterol within human atherosclerotic lesions using the fluorescent probe filipin. Atherosclerosis (1984) 0.97
Increased urinary excretion of renal enzymes in idiopathic calcium oxalate nephrolithiasis. J Urol (1983) 0.96
Atorvastatin inhibits renal crystal retention in a rat stone forming model. J Urol (2008) 0.95
Metabolic and genetic influence on glucose metabolism in type 2 diabetic subjects--experiences from relatives and twin studies. Best Pract Res Clin Endocrinol Metab (2003) 0.92
Comparison of the pathology of interstitial plaque in human ICSF stone patients to NHERF-1 and THP-null mice. Urol Res (2010) 0.90
Insulin resistance increases the risk of urinary stone formation in a rat model of metabolic syndrome. BJU Int (2010) 0.89
Renal stone disease: a commentary on the nature and significance of Randall's plaque. Nephron Physiol (2011) 0.88
Renal acid excretion and intracellular pH in salt-sensitive genetic hypertension. J Clin Invest (1993) 0.88
Disturbance of acid-base balance in the young spontaneously hypertensive rat. Clin Sci (Lond) (1987) 0.86
Metabolic syndrome and the genesis of uric acid stones. J Ren Nutr (2011) 0.86
Metabolic syndrome and bariatric surgery in stone disease etiology. Curr Opin Urol (2011) 0.86
Aprt/Opn double knockout mice: osteopontin is a modifier of kidney stone disease severity. Kidney Int (2005) 0.85
Antioxidants and self-reported history of kidney stones: the National Health and Nutrition Examination Survey. J Endourol (2011) 0.83
Effects of hyperinsulinemia under the euglycemic condition on calcium and phosphate metabolism in non-obese normotensive subjects. Tohoku J Exp Med (1995) 0.83
Metabolic adverse effects of thiazide diuretics: the importance of normokalaemia. J Intern Med Suppl (1991) 0.83
The association of cardiovascular disease and metabolic syndrome with nephrolithiasis. Curr Opin Urol (2012) 0.83
Impact of statins on nephrolithiasis in hyperlipidemic patients: a 10-year review of an equal access health care system. Clin Nephrol (2013) 0.83
Risk factors for kidney stones in older women in the southern United States. Am J Med Sci (2001) 0.82
Impaired expression of an organic cation transporter, IMPT1, in a knockout mouse model for kidney stone disease. Urol Res (2003) 0.82
Why does atorvastatin inhibit renal crystal retention? Urol Res (2011) 0.82
[Inflammatory cytokines in the pathogenesis of atherosclerosis]. Nihon Rinsho (2011) 0.82
Salt sensitivity and insulin resistance: Is there a link? Blood Press Suppl (1996) 0.80
The regulation of renal ammoniagenesis in the rat by extracellular factors. III. Effects of various fuels on in vitro ammoniagenesis. Metabolism (1983) 0.78
Re: Increased risk of diabetes in patients with urinary calculi: a 5-year followup study: S.-D. Chung, Y.-K. Chen and H.-C. Lin J Urol 2011; 186: 1888-1893. J Urol (2012) 0.76
[Cytokines in the pathogenesis of atherosclerosis]. Dtsch Med Wochenschr (2002) 0.76
Relationship between metabolic syndrome and multinodular non-toxic goiter in an inpatient population from a geographic area with moderate iodine deficiency. J Endocrinol Invest (2011) 0.75